Cencora (ABG) Stock Forecast & Price Target

Compare

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABG Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Cencora

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABG Stock 12 Month Forecast

Average Price Target

€355.29

▲(14.55% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Cencora in the last 3 months. The average price target is €355.29 with a high forecast of €373.54 and a low forecast of €339.58. The average price target represents a 14.55% change from the last price of €310.15.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"234":"€234","269":"€269","304":"€304","339":"€339","374":"€374"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":373.542334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€373.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":355.289697225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€355.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":339.58394,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€339.58</span>\n  </div></div>","useHTML":true}}],"tickPositions":[234,269,304,339,374],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,298.903,304.64448723076924,310.38597446153847,316.1274616923077,321.8689489230769,327.61043615384614,333.35192338461536,339.09341061538464,344.83489784615386,350.5763850769231,356.3178723076923,362.05935953846154,367.80084676923076,{"y":373.542334,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,298.903,303.24043824807694,307.57787649615386,311.9153147442308,316.2527529923077,320.5901912403846,324.92762948846155,329.26506773653847,333.6025059846154,337.9399442326923,342.27738248076923,346.61482072884615,350.9522589769231,{"y":355.289697225,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,298.903,302.0323030769231,305.16160615384615,308.2909092307692,311.42021230769234,314.5495153846154,317.67881846153847,320.80812153846153,323.9374246153846,327.06672769230767,330.1960307692308,333.32533384615385,336.4546369230769,{"y":339.58394,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":244.328,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":235.502,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.281,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.231,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250.997,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.874,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.397,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":266.678,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":292.892,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":312.43,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288.72,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":298.903,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€373.54

Average Price Target€355.29

Lowest Price Target€339.58

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Glen Santangelo

Barclays

€338.23→€359.37

Buy

15.87%

Upside

Reiterated

02/13/26

Lisa Gill

J.P. Morgan

€352.6→€354.29

Buy

14.23%

Upside

Reiterated

02/10/26

Cencora price target raised to $419 from $417 at JPMorganCencora price target raised to $419 from $417 at JPMorgan

Stephen Baxter

Wells Fargo

€342.46→€362.75

Buy

16.96%

Upside

Reiterated

02/10/26

Cencora price target raised to $429 from $405 at Wells FargoCencora price target raised to $429 from $405 at Wells Fargo

Charles Rhyee

TD Cowen

€338.23

Buy

9.05%

Upside

Reiterated

02/09/26

Cencora: OneOncology Acquisition and Conservative Guidance Underscore Upside to $400 Target

Elizabeth Anderson CFA

Evercore ISI

€372.05→€355.14

Buy

14.51%

Upside

Reiterated

02/05/26

Cencora price target lowered to $420 from $440 at Evercore ISICencora price target lowered to $420 from $440 at Evercore ISI

Erin Wright

Morgan Stanley

€338.23

Buy

9.05%

Upside

Upgraded

01/29/26

Cencora upgraded to Overweight from Equal Weight at Morgan StanleyCencora upgraded to Overweight from Equal Weight at Morgan Stanley

Brian Tanquilut

Jefferies

€279.04→€372.05

Buy

19.96%

Upside

Upgraded

01/22/26

Cencora upgraded to Buy from Hold at JefferiesCencora upgraded to Buy from Hold at Jefferies

Allen Lutz

Bank of America Securities

―

Hold

―

Reiterated

01/16/26

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (NASDAQ: FDMT), Centene (NYSE: CNC) and Cencora (NYSE: COR)

Eric Coldwell

Robert W. Baird

€331.46→€350.91

Buy

13.14%

Upside

Reiterated

01/13/26

Cencora price target raised to $415 from $392 at BairdCencora price target raised to $415 from $392 at Baird

George Hill

Deutsche Bank

€272.27→€313.71

Buy

1.15%

Upside

Reiterated

11/07/25

Cencora price target raised to $371 from $322 at Deutsche BankCencora price target raised to $371 from $322 at Deutsche Bank

Kevin Caliendo

UBS

€321.32→€350.91

Buy

13.14%

Upside

Reiterated

11/07/25

Cencora's Strong Growth Potential and Market Position Justify Buy Rating and Increased Price Target

Steven Valiquette

Mizuho Securities

€287.49→€321.32

Buy

3.60%

Upside

Reiterated

11/06/25

Cencora price target raised to $380 from $340 at MizuhoCencora price target raised to $380 from $340 at Mizuho

Michael Cherny

Leerink Partners

€295.1→€305.25

Buy

-1.58%

Downside

Reiterated

10/06/25

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (NASDAQ: IDXX), Cencora (NYSE: COR) and Amgen (NASDAQ: AMGN)

Daniel Grosslight

Citi

€279.04→€300.18

Buy

-3.22%

Downside

Reiterated

05/08/25

Cencora price target raised to $355 from $330 at CitiCencora price target raised to $355 from $330 at Citi

David Toung

Argus Research

€228.3→€236.76

Buy

-23.66%

Downside

Reiterated

02/28/25

Cencora price target raised to $280 from $270 at ArgusCencora price target raised to $280 from $270 at Argus

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Glen Santangelo

Barclays

€338.23→€359.37

Buy

15.87%

Upside

Reiterated

02/13/26

Lisa Gill

J.P. Morgan

€352.6→€354.29

Buy

14.23%

Upside

Reiterated

02/10/26

Cencora price target raised to $419 from $417 at JPMorganCencora price target raised to $419 from $417 at JPMorgan

Stephen Baxter

Wells Fargo

€342.46→€362.75

Buy

16.96%

Upside

Reiterated

02/10/26

Cencora price target raised to $429 from $405 at Wells FargoCencora price target raised to $429 from $405 at Wells Fargo

Charles Rhyee

TD Cowen

€338.23

Buy

9.05%

Upside

Reiterated

02/09/26

Cencora: OneOncology Acquisition and Conservative Guidance Underscore Upside to $400 Target

Elizabeth Anderson CFA

Evercore ISI

€372.05→€355.14

Buy

14.51%

Upside

Reiterated

02/05/26

Cencora price target lowered to $420 from $440 at Evercore ISICencora price target lowered to $420 from $440 at Evercore ISI

Erin Wright

Morgan Stanley

€338.23

Buy

9.05%

Upside

Upgraded

01/29/26

Cencora upgraded to Overweight from Equal Weight at Morgan StanleyCencora upgraded to Overweight from Equal Weight at Morgan Stanley

Brian Tanquilut

Jefferies

€279.04→€372.05

Buy

19.96%

Upside

Upgraded

01/22/26

Cencora upgraded to Buy from Hold at JefferiesCencora upgraded to Buy from Hold at Jefferies

Allen Lutz

Bank of America Securities

―

Hold

―

Reiterated

01/16/26

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (NASDAQ: FDMT), Centene (NYSE: CNC) and Cencora (NYSE: COR)

Eric Coldwell

Robert W. Baird

€331.46→€350.91

Buy

13.14%

Upside

Reiterated

01/13/26

Cencora price target raised to $415 from $392 at BairdCencora price target raised to $415 from $392 at Baird

George Hill

Deutsche Bank

€272.27→€313.71

Buy

1.15%

Upside

Reiterated

11/07/25

Cencora price target raised to $371 from $322 at Deutsche BankCencora price target raised to $371 from $322 at Deutsche Bank

Kevin Caliendo

UBS

€321.32→€350.91

Buy

13.14%

Upside

Reiterated

11/07/25

Cencora's Strong Growth Potential and Market Position Justify Buy Rating and Increased Price Target

Steven Valiquette

Mizuho Securities

€287.49→€321.32

Buy

3.60%

Upside

Reiterated

11/06/25

Cencora price target raised to $380 from $340 at MizuhoCencora price target raised to $380 from $340 at Mizuho

Michael Cherny

Leerink Partners

€295.1→€305.25

Buy

-1.58%

Downside

Reiterated

10/06/25

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (NASDAQ: IDXX), Cencora (NYSE: COR) and Amgen (NASDAQ: AMGN)

Daniel Grosslight

Citi

€279.04→€300.18

Buy

-3.22%

Downside

Reiterated

05/08/25

Cencora price target raised to $355 from $330 at CitiCencora price target raised to $355 from $330 at Citi

David Toung

Argus Research

€228.3→€236.76

Buy

-23.66%

Downside

Reiterated

02/28/25

Cencora price target raised to $280 from $270 at ArgusCencora price target raised to $280 from $270 at Argus

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cencora

3 Months

xxx

Success Rate

17/23 ratings generated profit

Average Return

+6.35%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.91% of your transactions generating a profit, with an average return of +6.35% per trade.

1 Year

Elizabeth Anderson CFAEvercore ISI

Success Rate

23/23 ratings generated profit

Average Return

+24.26%

reiterated a buy rating 20 days ago

Copying Elizabeth Anderson CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +24.26% per trade.

2 Years

xxx

Success Rate

23/23 ratings generated profit

Average Return

+43.51%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +43.51% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABG Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABG has received 38 Buy Ratings, 49 Hold Ratings, and 0 Sell Ratings. ABG average Analyst price target in the past 3 months is 355.29.

Each month's total comprises the sum of three months' worth of ratings.

ABG Financial Forecast

ABG Earnings Forecast

Next quarter’s earnings estimate for ABG is €4.13 with a range of €3.99 to €4.32. The previous quarter’s EPS was €3.46. ABG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ABG has Performed in-line its overall industry.

ABG Sales Forecast

Next quarter’s sales forecast for ABG is €68.96B with a range of €67.96B to €69.93B. The previous quarter’s sales results were €72.86B. ABG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ABG has Performed in-line its overall industry.

ABG Stock Forecast FAQ

What is DE:ABG’s average 12-month price target, according to analysts?

Based on analyst ratings, Cencora, Inc.’s 12-month average price target is 355.29.

What is DE:ABG’s upside potential, based on the analysts’ average price target?

Cencora, Inc. has 14.55% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Cencora, Inc. a Buy, Sell or Hold?

Cencora, Inc. has a consensus rating of Strong Buy, which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Cencora, Inc.’s share price target?

The average share price target for Cencora, Inc. is 355.29. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €373.54 ,and the lowest forecast is €339.58. The average share price target represents 14.55% Increase from the current price of €310.15.

What do analysts say about Cencora, Inc.?

Cencora, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Cencora, Inc.?

To buy shares of DE:ABG, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Cencora (ABG) Stock Forecast & Price Target

ABG Analyst Ratings

ABG Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cencora

ABG Analyst Recommendation Trends

ABG Financial Forecast

ABG Earnings Forecast

ABG Sales Forecast

ABG Stock Forecast FAQ

Detailed List of Analyst Forecasts